Plasmapheresis combined with lymphocytapheresis and cytotoxic drugs as a therapeutic modality in neuroimmunological diseases.
Rebound after plasmapheresis is thought to be due to enhanced antibody and/or immune complex production. To prevent rebound a combination of steroids and immunosuppressive drugs has been used: lymphocytapheresis was employed in most patients, for not more than 10 sessions. 50 patients with myasthenia gravis, inflammatory myopathy, chronic dysimmune polyneuropathy and immune complex polyneuropathy have been treated and long-lasting benefits obtained in 35 patients. Rebound effects were observed only when cytotoxic drugs were not given or discontinued too soon. 8 patients who had been treated by plasmapheresis combined with steroids alone, after some recurrences of their disease, were switched to cytotoxic drugs, steroids and lymphocytapheresis combined with plasma exchange: in this group 7 patients eventually gained long lasting remissions. Our clinical experience strongly supports the hypothesis of a synergy between plasmapheresis and immuno-suppressive measures.
D001327:Autoimmune Diseases / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007105:Immune Complex Diseases / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008214:Lymphocytes; D009135:Muscular Diseases / Q000628:therapy; D009157:Myasthenia Gravis / Q000628:therapy; D009422:Nervous System Diseases / Q000628:therapy*; D010523:Peripheral Nervous System Diseases / Q000628:therapy; D010956:Plasmapheresis; D011129:Polyradiculoneuropathy / Q000628:therapy
D007166:Immunosuppressive Agents